We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Pharma companies should use risk analysis procedures to
decide which aspects of their computer systems need validation testing, rather than wasting time and money attempting to test everything, G. Raymond Miller, president of Miller Regulatory Consulting, said during a recent FDAnews audio conference.